Company Overview and News

 
The top 10 cities for finding a job in 2018

2018-04-11 cnbc
If one of your top goals for the year is to find a new job then you're not alone.
Upvote Downvote

 
Workiva: Working For Profits

2018-04-04 seekingalpha
Workiva's product is superior to the competition and possesses attractive unit economics which are set to improve over the next 3-5 years as the company pursues enterprise customers.
Upvote Downvote

 
This Is What Record-Low Unemployment Looks Like in America - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Workiva (WK) Prospects Appear Bleak: Should You Offload?

2018-03-14 zacks
In case Workiva Inc. (WK - Free Report) shares are still in your portfolio, it’s high time to get rid of the stock. The odds in favor of an upside in the near term are slim. The stock has underperformed the industry in the past six months. Workiva’s shares have returned 20.4% in the past six months, compared with the industry’s rally of 25.9%. Let’s explore the aspects that are responsible for the downslide faced by this Zacks Rank #4 (Sell) stock.
Upvote Downvote

 
Workiva Partners with Anaplan to Enhance Wdesk Performance

2018-03-09 zacks
Workiva Inc. (WK - Free Report) recently teamed up with Anaplan, a globally recognized name in Connected Planning. The partnership is related to streamlining the process of performance management reporting. Workiva’s flagship product, Wdesk cloud platform, is now integrated with Anaplan’s Connected Planning platform.
Upvote Downvote

 
WK / Workiva, Inc. 8-K (Current Report)

2018-03-06 sec.gov
Document UNITED STATES
Upvote Downvote

 
Workiva (WK) Posts Wider Loss in Q4, Wdesk Adoption Strong

2018-02-23 zacks
Workiva Inc. (WK - Free Report) reported fourth-quarter 2017 loss of 19 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 22 cents. However, the figure was significantly wider than the year-ago quarter’s loss of 9 cents. Total revenues increased 17.5% year over year to $54.5 million, slightly better than the Zacks Consensus Estimate of $53.3 million. The company continued to add Wdesk users.
Upvote Downvote

1
Workiva's (WK) CEO Matt Rizai on Q4 2017 Results - Earnings Call Transcript

2018-02-23 seekingalpha
Good afternoon. My name is Jessie, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Workiva, Fourth Quarter and Full Year 2017 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
Upvote Downvote

 
WK / Workiva, Inc. 8-K (Current Report)

2018-02-22 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2018 Date of Report (date of earliest event reported) ___________________________________ WORKIVA INC. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of inco
Upvote Downvote

 
Workiva (WK) to Report Q4 Earnings: What's in the Cards?

2018-02-20 zacks
Workiva Inc. (WK - Free Report) is set to report fourth-quarter 2017 results on Feb 22. Although the company reported loss in each of the trailing four quarters, it surpassed the Zack Consensus Estimate, delivering an average positive earnings surprise of 45.29%. Last quarter, the company reported a loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 29 cents. Revenues increased 16.
Upvote Downvote

 
WK / Workiva, Inc. / Behar Living Trust - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Workiva Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 98139A105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) ý Rule 13d-1(d)   *The remainder of
Upvote Downvote

 
WK / Workiva, Inc. / Behar Living Trust - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Workiva Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 98139A105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) ý Rule 13d-1(d)   *The remainder of
Upvote Downvote

 
WK / Workiva, Inc. / VANDERPLOEG MARTIN J - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Workiva Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 98139A105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) ý Rule 13d-1(d)   *The remainder of
Upvote Downvote

 
WK / Workiva, Inc. / TROM JEFF D - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Workiva Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 98139A105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) ý Rule 13d-1(d)   *The remainder of
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 98139A105